Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low-grade endometrial stromal sarcoma: hormonal aspects.

Micheline C Chu1, Gil Mor, Chungyun Lim

  • 1Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06520, USA.

Gynecologic Oncology
|June 25, 2003
PubMed
Summary

Estrogen replacement therapy may worsen outcomes for low-grade endometrial stromal sarcoma patients. Progestin therapy shows promise for treating recurrences and as adjuvant therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Environmental Benzene Exposure Induces a Conserved Neutrophil Degranulation Program Across Species.

Toxicological sciences : an official journal of the Society of Toxicology·2026
Same author

Type I Interferon Regulation of HLA-F Expression in Human Trophoblasts During Viral Infection.

Viruses·2026
Same author

Sex-specific in utero reprogramming of lung immunity.

Mucosal immunology·2026
Same author

Trained Memory of Uterine Macrophages Improves Subsequent Pregnancy Outcomes.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

High repetitive frequency pulsed magnetic fields modulate macrophage M2 polarization and ameliorate inflammation-induced murine abortion†.

Biology of reproduction·2026
Same author

Micropeptide YG-6 encoded by exosomal LINC01123 derived from highly migratory ovarian cancer cells promotes tumor progression.

Molecular cancer·2026

Area of Science:

  • Gynecologic Oncology
  • Endocrinology
  • Cancer Research

Background:

  • Low-grade endometrial stromal sarcoma (ESS) is a rare uterine malignancy.
  • Hormonal influences, particularly estrogen and progestin, are implicated in ESS development and progression.

Purpose of the Study:

  • To investigate the impact of estrogen exposure on clinical outcomes in patients with low-grade ESS.
  • To evaluate the role of estrogen and progestin receptors in ESS and the efficacy of progestin therapy.

Main Methods:

  • Retrospective review of 22 low-grade ESS patients.
  • Analysis of hormone receptor status (Estrogen Receptor alpha/beta, Progestin Receptor) via immunohistochemistry and RT-PCR.
  • Assessment of exposure to exogenous/endogenous estrogen and progestins post-diagnosis.

Related Experiment Videos

Main Results:

  • Estrogen replacement therapy (ERT) was associated with a high recurrence rate (80%).
  • Progestin therapy demonstrated efficacy in treating recurrent ESS, with 88% showing stable disease or complete response.
  • Lack of Estrogen Receptor beta expression in ESS suggests a potential marker for malignancy.

Conclusions:

  • Estrogen replacement therapy may be detrimental for low-grade ESS patients.
  • Progestin therapy is recommended for adjuvant treatment and management of recurrent low-grade ESS.
  • Loss of Estrogen Receptor beta may indicate malignancy in endometrial stromal sarcomas.